A Novel Approach for Developing and Interpreting Treatment Moderator Profiles in Randomized Clinical Trials
IMPORTANCE Identifying treatment moderators may help mental health practitioners arrive at more precise treatment selection for individual patients and can focus clinical research on subpopulations that differ in treatment response. OBJECTIVE To demonstrate a novel exploratory approach to moderation...
Gespeichert in:
| Veröffentlicht in: | JAMA psychiatry (Chicago, Ill.) Ill.), 2013-11, Vol.70 (11), p.1241-1247 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1247 |
|---|---|
| container_issue | 11 |
| container_start_page | 1241 |
| container_title | JAMA psychiatry (Chicago, Ill.) |
| container_volume | 70 |
| creator | Wallace, Meredith L Frank, Ellen Kraemer, Helena C |
| description | IMPORTANCE Identifying treatment moderators may help mental health practitioners arrive at more precise treatment selection for individual patients and can focus clinical research on subpopulations that differ in treatment response. OBJECTIVE To demonstrate a novel exploratory approach to moderation analysis in randomized clinical trials. DESIGN, SETTING, AND PARTICIPANTS A total of 291 adults from a randomized clinical trial that compared an empirically supported psychotherapy with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy as treatments for depression. MAIN OUTCOMES AND MEASURES We selected 8 relatively independent individual moderators out of 32 possible variables. A combined moderator, M*, was developed as a weighted combination of the 8 selected individual moderators. M* was then used to identify individuals for whom psychotherapy may be preferred to SSRI pharmacotherapy or vice versa. RESULTS Among individual moderators, psychomotor activation had the largest moderator effect size (0.12; 95% CI, |
| doi_str_mv | 10.1001/jamapsychiatry.2013.1960 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1449769612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>1737172</ama_id><sourcerecordid>3127584721</sourcerecordid><originalsourceid>FETCH-LOGICAL-a508t-6330703c721c137b6cab8b2fd2be5ecafc409744f9e6f20b3569dd59529c03773</originalsourceid><addsrcrecordid>eNpdkVuLFDEQhYMo7rLuH_BBAiL4MmNuncvjMN4W1guygm9NOl1xM3YnbdIjjL_eNDPuonmpUHwnpyoHIUzJmhJCX-3saKdycLfBzvmwZoTyNTWSPEDnjEq9kozrh3d39u0MXZayI_VoQgTXj9EZE0Ro1uhz9GODP6ZfMODNNOVk3S32KePXUFtpCvE7trHHV3GGPGWYl8ZNBjuPEGf8IfWQ7Vz5zzn5MEDBIeIvVZHG8Bt6vB1CDM4OVRPsUJ6gR74WuDzVC_T17Zub7fvV9ad3V9vN9co2RM8ryTlRhDvFqKNcddLZTnfM96yDBpz1ThCjhPAGpGek4400fd-YhhlHuFL8Ar08vls3-rmHMrdjKA6GwUZI-9JSIYySRlJW0ef_obu0z7FOV6lGS84YN5XSR8rlVEoG3045jDYfWkraJZP230zaJZN2yaRKn50M9t0I_Z3wbwIVeHECbKlf5bONLpR7ThMmmFy4p0euOt3bK66oYvwPti6hnw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1458632239</pqid></control><display><type>article</type><title>A Novel Approach for Developing and Interpreting Treatment Moderator Profiles in Randomized Clinical Trials</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Wallace, Meredith L ; Frank, Ellen ; Kraemer, Helena C</creator><creatorcontrib>Wallace, Meredith L ; Frank, Ellen ; Kraemer, Helena C</creatorcontrib><description>IMPORTANCE Identifying treatment moderators may help mental health practitioners arrive at more precise treatment selection for individual patients and can focus clinical research on subpopulations that differ in treatment response. OBJECTIVE To demonstrate a novel exploratory approach to moderation analysis in randomized clinical trials. DESIGN, SETTING, AND PARTICIPANTS A total of 291 adults from a randomized clinical trial that compared an empirically supported psychotherapy with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy as treatments for depression. MAIN OUTCOMES AND MEASURES We selected 8 relatively independent individual moderators out of 32 possible variables. A combined moderator, M*, was developed as a weighted combination of the 8 selected individual moderators. M* was then used to identify individuals for whom psychotherapy may be preferred to SSRI pharmacotherapy or vice versa. RESULTS Among individual moderators, psychomotor activation had the largest moderator effect size (0.12; 95% CI, <.01 to 0.24). The combined moderator, M*, had a larger moderator effect size than any individual moderator (0.31; 95% CI, 0.15 to 0.46). Although the original analyses demonstrated no overall difference in treatment response, M* divided the study population into 2 subpopulations, with each showing a clinically significant difference in response to psychotherapy vs SSRI pharmacotherapy. CONCLUSIONS AND RELEVANCE Our results suggest that the strongest determinations for personalized treatment selection will likely require simultaneous consideration of multiple moderators, emphasizing the value of the methods presented here. After validation in a randomized clinical trial, a mental health practitioner could input a patient’s relevant baseline values into a handheld computer programmed with the weights needed to calculate M*. The device could then output the patient’s M* value and suggested treatment, thereby allowing the mental health practitioner to select the treatment that would offer the greatest likelihood of success for each patient.</description><identifier>ISSN: 2168-622X</identifier><identifier>EISSN: 2168-6238</identifier><identifier>DOI: 10.1001/jamapsychiatry.2013.1960</identifier><identifier>PMID: 24048258</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Adult ; Biological and medical sciences ; Clinical trials ; Effect Modifier, Epidemiologic ; Female ; Humans ; Male ; Medical sciences ; Mental depression ; Mental health care ; Models, Statistical ; Patient Selection ; Precision Medicine - methods ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychotherapy ; Randomized Controlled Trials as Topic - methods</subject><ispartof>JAMA psychiatry (Chicago, Ill.), 2013-11, Vol.70 (11), p.1241-1247</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright American Medical Association Nov 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a508t-6330703c721c137b6cab8b2fd2be5ecafc409744f9e6f20b3569dd59529c03773</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/articlepdf/10.1001/jamapsychiatry.2013.1960$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2013.1960$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,776,780,3327,27901,27902,76232,76235</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28024268$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24048258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wallace, Meredith L</creatorcontrib><creatorcontrib>Frank, Ellen</creatorcontrib><creatorcontrib>Kraemer, Helena C</creatorcontrib><title>A Novel Approach for Developing and Interpreting Treatment Moderator Profiles in Randomized Clinical Trials</title><title>JAMA psychiatry (Chicago, Ill.)</title><addtitle>JAMA Psychiatry</addtitle><description>IMPORTANCE Identifying treatment moderators may help mental health practitioners arrive at more precise treatment selection for individual patients and can focus clinical research on subpopulations that differ in treatment response. OBJECTIVE To demonstrate a novel exploratory approach to moderation analysis in randomized clinical trials. DESIGN, SETTING, AND PARTICIPANTS A total of 291 adults from a randomized clinical trial that compared an empirically supported psychotherapy with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy as treatments for depression. MAIN OUTCOMES AND MEASURES We selected 8 relatively independent individual moderators out of 32 possible variables. A combined moderator, M*, was developed as a weighted combination of the 8 selected individual moderators. M* was then used to identify individuals for whom psychotherapy may be preferred to SSRI pharmacotherapy or vice versa. RESULTS Among individual moderators, psychomotor activation had the largest moderator effect size (0.12; 95% CI, <.01 to 0.24). The combined moderator, M*, had a larger moderator effect size than any individual moderator (0.31; 95% CI, 0.15 to 0.46). Although the original analyses demonstrated no overall difference in treatment response, M* divided the study population into 2 subpopulations, with each showing a clinically significant difference in response to psychotherapy vs SSRI pharmacotherapy. CONCLUSIONS AND RELEVANCE Our results suggest that the strongest determinations for personalized treatment selection will likely require simultaneous consideration of multiple moderators, emphasizing the value of the methods presented here. After validation in a randomized clinical trial, a mental health practitioner could input a patient’s relevant baseline values into a handheld computer programmed with the weights needed to calculate M*. The device could then output the patient’s M* value and suggested treatment, thereby allowing the mental health practitioner to select the treatment that would offer the greatest likelihood of success for each patient.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Effect Modifier, Epidemiologic</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Mental health care</subject><subject>Models, Statistical</subject><subject>Patient Selection</subject><subject>Precision Medicine - methods</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychotherapy</subject><subject>Randomized Controlled Trials as Topic - methods</subject><issn>2168-622X</issn><issn>2168-6238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkVuLFDEQhYMo7rLuH_BBAiL4MmNuncvjMN4W1guygm9NOl1xM3YnbdIjjL_eNDPuonmpUHwnpyoHIUzJmhJCX-3saKdycLfBzvmwZoTyNTWSPEDnjEq9kozrh3d39u0MXZayI_VoQgTXj9EZE0Ro1uhz9GODP6ZfMODNNOVk3S32KePXUFtpCvE7trHHV3GGPGWYl8ZNBjuPEGf8IfWQ7Vz5zzn5MEDBIeIvVZHG8Bt6vB1CDM4OVRPsUJ6gR74WuDzVC_T17Zub7fvV9ad3V9vN9co2RM8ryTlRhDvFqKNcddLZTnfM96yDBpz1ThCjhPAGpGek4400fd-YhhlHuFL8Ar08vls3-rmHMrdjKA6GwUZI-9JSIYySRlJW0ef_obu0z7FOV6lGS84YN5XSR8rlVEoG3045jDYfWkraJZP230zaJZN2yaRKn50M9t0I_Z3wbwIVeHECbKlf5bONLpR7ThMmmFy4p0euOt3bK66oYvwPti6hnw</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Wallace, Meredith L</creator><creator>Frank, Ellen</creator><creator>Kraemer, Helena C</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20131101</creationdate><title>A Novel Approach for Developing and Interpreting Treatment Moderator Profiles in Randomized Clinical Trials</title><author>Wallace, Meredith L ; Frank, Ellen ; Kraemer, Helena C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a508t-6330703c721c137b6cab8b2fd2be5ecafc409744f9e6f20b3569dd59529c03773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Effect Modifier, Epidemiologic</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Mental health care</topic><topic>Models, Statistical</topic><topic>Patient Selection</topic><topic>Precision Medicine - methods</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychotherapy</topic><topic>Randomized Controlled Trials as Topic - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wallace, Meredith L</creatorcontrib><creatorcontrib>Frank, Ellen</creatorcontrib><creatorcontrib>Kraemer, Helena C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA psychiatry (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wallace, Meredith L</au><au>Frank, Ellen</au><au>Kraemer, Helena C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Novel Approach for Developing and Interpreting Treatment Moderator Profiles in Randomized Clinical Trials</atitle><jtitle>JAMA psychiatry (Chicago, Ill.)</jtitle><addtitle>JAMA Psychiatry</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>70</volume><issue>11</issue><spage>1241</spage><epage>1247</epage><pages>1241-1247</pages><issn>2168-622X</issn><eissn>2168-6238</eissn><abstract>IMPORTANCE Identifying treatment moderators may help mental health practitioners arrive at more precise treatment selection for individual patients and can focus clinical research on subpopulations that differ in treatment response. OBJECTIVE To demonstrate a novel exploratory approach to moderation analysis in randomized clinical trials. DESIGN, SETTING, AND PARTICIPANTS A total of 291 adults from a randomized clinical trial that compared an empirically supported psychotherapy with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy as treatments for depression. MAIN OUTCOMES AND MEASURES We selected 8 relatively independent individual moderators out of 32 possible variables. A combined moderator, M*, was developed as a weighted combination of the 8 selected individual moderators. M* was then used to identify individuals for whom psychotherapy may be preferred to SSRI pharmacotherapy or vice versa. RESULTS Among individual moderators, psychomotor activation had the largest moderator effect size (0.12; 95% CI, <.01 to 0.24). The combined moderator, M*, had a larger moderator effect size than any individual moderator (0.31; 95% CI, 0.15 to 0.46). Although the original analyses demonstrated no overall difference in treatment response, M* divided the study population into 2 subpopulations, with each showing a clinically significant difference in response to psychotherapy vs SSRI pharmacotherapy. CONCLUSIONS AND RELEVANCE Our results suggest that the strongest determinations for personalized treatment selection will likely require simultaneous consideration of multiple moderators, emphasizing the value of the methods presented here. After validation in a randomized clinical trial, a mental health practitioner could input a patient’s relevant baseline values into a handheld computer programmed with the weights needed to calculate M*. The device could then output the patient’s M* value and suggested treatment, thereby allowing the mental health practitioner to select the treatment that would offer the greatest likelihood of success for each patient.</abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>24048258</pmid><doi>10.1001/jamapsychiatry.2013.1960</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-622X |
| ispartof | JAMA psychiatry (Chicago, Ill.), 2013-11, Vol.70 (11), p.1241-1247 |
| issn | 2168-622X 2168-6238 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1449769612 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Adult Biological and medical sciences Clinical trials Effect Modifier, Epidemiologic Female Humans Male Medical sciences Mental depression Mental health care Models, Statistical Patient Selection Precision Medicine - methods Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychotherapy Randomized Controlled Trials as Topic - methods |
| title | A Novel Approach for Developing and Interpreting Treatment Moderator Profiles in Randomized Clinical Trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T15%3A38%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Novel%20Approach%20for%20Developing%20and%20Interpreting%20Treatment%20Moderator%20Profiles%20in%20Randomized%20Clinical%20Trials&rft.jtitle=JAMA%20psychiatry%20(Chicago,%20Ill.)&rft.au=Wallace,%20Meredith%20L&rft.date=2013-11-01&rft.volume=70&rft.issue=11&rft.spage=1241&rft.epage=1247&rft.pages=1241-1247&rft.issn=2168-622X&rft.eissn=2168-6238&rft_id=info:doi/10.1001/jamapsychiatry.2013.1960&rft_dat=%3Cproquest_cross%3E3127584721%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1458632239&rft_id=info:pmid/24048258&rft_ama_id=1737172&rfr_iscdi=true |